FBT News and Press, First Trust Amex Biotech Index Fund From 02/25/22

FBT is a passive biotechnology ETF, which doesn’t pay any dividend. Baring the past one year, FBT’s price return has outperformed the S&P 500. Effective portfolio rebalancing may determine its future growth. For further details see: FBT: A Long Term Hol...

The macroeconomic backdrop of Fed interest rate hikes is rapidly deflating overvalued technology companies and "crypto-collectibles." We expect the technology sector to underperform value and biotech. After the sell-off, biotech companies' valuation is close to the 2018 level even tho...

No matter how long is the time you dedicate to look at/hold AbbVie, it's a "movie" with a happy ending, with a second-to-none acting performance. In spite of near-future growth concerns, and even if the stock might be (technically/optically) looking fully valued, we believe that there...

The goal of the DDM is to quickly and easily utilize available resources of an asset to understand what the intrinsic value of that asset is based on certain market and company expectations. If the required return component of the equation rises without expectations of higher company ...

The anticipated end of the pandemic causes volatility because a transition phase will be priced as a new rotation from, for example, defensive staples to healthcare. Healthcare ETFs can add a defense to a portfolio that is overweight cyclicals, energy, and financials. US Airlines ...

At the end of 2019, had we been told that a two-year pandemic was about to begin, we would have found it impossible to predict the set of returns that followed in subsequent years. Historically, “tightening,” or “over-tightening,” policy was about corrallin...

Aeta: We know the transmissibility is higher for the omicron variant and will impact vaccine efficacy, but anecdotal hospital reports suggest that it milder. Aeta: Health care is having a solid year but is still lagging the market, as cyclicals are outperforming due to the strong econ...

While inflation was at first believed to be transitory, it is now beginning to look persistent. Biotech stocks are close to 6.5% of the Russell 2000 Value Index benchmark, and only a few have earnings and positive cash flows. We also think the outlook is rosy for small-cap value i...

With each new outbreak and variant, comes new fears, government lockdowns and hopes for recovery through science and medicine in the form of effective vaccines. Until recently, investor mindsets had shifted to a “living with COVID-19” mentality, supported by abundant sti...

The latest IHS Markit US Sector PMI revealed that six of the seven broad sectors tracked by the surveys reported higher output in November. Despite some of the supply chain problems having eased in November, the extent to which production growth had been constrained is consistent with...